Skip to main content
. 2021 Feb 16;11(2):e038349. doi: 10.1136/bmjopen-2020-038349

Table 2.

Subtypes of haematological and patients with solid tumour presenting to the emergency department with sepsis

Oncology patients (N=442)
Total haematological tumours, n (%) Underwent BMT, n (%) 28 (6.3)
Leukaemia, n (%) Total 80 (18.1)
ALL, n (%) 23 (5.2)
AML, n (%) 36 (8.1)
CML, n (%) 1 (0.2)
CLL, n (%) 18 (4.1)
Hairy cell leukaemia, n (%) 2 (0.5)
Lymphoma, n (%) Hodgkin’s, n (%) 10 (2.3)
Non-Hodgkin’s, n (%) 29 (6.6)
Multiple myeloma, n (%) 11 (2.5)
Myelodysplasia, n (%) 7 (1.6)
Total solid tumours, n (%) Lung, n (%) 69 (15.6)
Thyroid, n (%) 6 (1.4)
Ovarian, n (%) 10 (2.3)
Breast, n (%) 42 (9.5)
Prostate, n (%) 29 (6.6)
Liver, n (%) 8 (1.8)
Gastric, n (%) 15 (3.4)
Cervical, n (%) 2 (0.5)
Bladder, n (%) 16 (3.6)
Colorectal, n (%) 30 (6.8)
Kidney, n (%) 8 (1.8)
Gallbladder, n (%) 13 (2.9)
Pancreatic, n (%) 36 (8.1)
Other, n (%) 21 (4.75)

ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; BMT, bone marrow transplant; CLL, chronic lymphocytic leukaemia; CML, chronic myeloid leukaemia.